PoNS
Commercial- Indications
- Multiple sclerosis gait deficit, Mild-to-moderate traumatic brain injury balance deficit
Company intelligence / Profile preview
PoNS Therapy has demonstrated clinical benefit as an adjunctive treatment for improving gait and balance deficits. Recent open-label observational studies confirm a linear relationship between adherence to PoNS Therapy and improvement in Dynamic Gait Index scores among people with MS. The therapy has received regulatory authorizations across the US, Canada, and Australia.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Helius Medical Technologies.